Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130312 · ClinicalTrials.gov registry record · Phase 4
Effect of Sulodexide in Overt Diabetic Nephropathy
A Phase 4 study, sponsored by Keryx Biopharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 968
- Enrollment target
NCT00130312: Clinical Trial Phase 4 study, sponsored by Keryx Biopharmaceuticals.
NCT00130312 is a Phase 4 study that was terminated before completion, run by Keryx Biopharmaceuticals. The registered enrollment target is 968 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00130312, a Phase 4 study, was terminated before completion, sponsored by Keryx Biopharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 968 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether sulodexide is effective in slowing or preventing the progression of diabetic kidney disease.
Primary Outcome
Time in study depended on time to doubling of serum creatinine and when the patient was enrolled in the trial.
Interventions
- DRUG Placebo
- DRUG Sulodexide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 968 participants |
| Start Date | 2005-08 |
| Est. Completion | 2008-03 |
| Phase | Phase 4 |
Why NCT00130312 stopped before completion
NCT00130312 is an interventional study that assigns participants to a tested intervention. The registered 968 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00130312 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00130312 about?
NCT00130312 is a clinical study titled "Effect of Sulodexide in Overt Diabetic Nephropathy". The purpose of this study is to determine whether sulodexide is effective in slowing or preventing the progression of diabetic kidney disease.
What is the current status of trial NCT00130312?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 968 participants. The study started on 2005-08. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00130312?
The interventions under investigation include: Placebo (DRUG), Sulodexide (DRUG).
Who is sponsoring clinical trial NCT00130312?
This trial is sponsored by Keryx Biopharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00130312's enrollment target sits among peer trials
968 75th of 2000 higher than 1,926 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05354141 · 970 participants · Phase 3
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia